Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
|Articles|September 16, 2008
- Nov30 2004
- Volume 11
- Issue 22
That's Entertainment
Advertisement
Physician's Money Digest
Forbes
Ever think you chose the wrong profession? With today's medical profession in some turmoil, more than a few physicians might. Although the average reader earns a good annual income ($184,000 after practice expenses), others who don't save lives every day are doing a lot better. Here are some numbers, courtesy of the 2004 "The Celebrity 100":
Articles in this issue
about 18 years ago
Check Your Creditabout 18 years ago
Female Millionairesabout 18 years ago
The Cadillac CDabout 18 years ago
Sales Taxes Deductibleabout 18 years ago
Risky Investments?about 18 years ago
Doc's Tax Dodges Probedabout 18 years ago
Thumbs Up: The IRS: On Your Side?about 18 years ago
Thumbs Down: They Have Some Nerveabout 18 years ago
Reading Room: There for the Takingabout 18 years ago
Living a Lot LongerAdvertisement
Related to this article
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
3
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
4
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
5